This study investigated the relationships of haemoglobin (Hb) A1c, anti-hyperglycaemic treatment, and potential risks of adverse effects with all-cause mortality in patients with type 2 diabetes. The gene discussed is GSTM1; the disease is type 2 diabetes mellitus.